Evidence that
moves your
therapy forward.
Purpose-built RWE programs for specialty biopharma — from strategy through late-stage research.
We generate fit-for-purpose evidence that supports the full product lifecycle — from integrated strategy to regulatory-grade analytics.
Our Evidence ApproachPrepared for you.
Getting from Taboo to Treatment: Understanding stigma and perceived gender differences in mental health and psychedelics
Cultural stigma around mental health, especially for men, remains a hidden barrier to diagnosis and care. This piece explores how psychedelic-assisted therapy may not only treat depression, but help dismantle the stigmas that prevent people from seeking help in the first place.
It Takes a Village: Engaging Stakeholders in the Emerging Psychedelics Space
As psychedelic-assisted therapies approach a potential inflection point in treatment-resistant depression, this whitepaper maps the distinct needs of four key stakeholder groups: patients, regulators, providers, and payers, and outlines how a rigorous real-world evidence strategy can help sponsors anticipate expectations, de-risk development, and improve outcomes.
Old Medicine, New Frameworks: the Often Overlooked Mind-Body Connection with Therapeutic Psychedelics
Up to 30% of depression patients don't respond to current treatments, making the case for rethinking how we approach mental health care. This piece traces how centuries of mind-body philosophy have shaped modern treatment paradigms and why the therapeutic context surrounding psychedelics may matter as much as the compounds themselves.
Oregon Psilocybin Service Centers are a Model for Patient-Centered Care
With the first FDA approval of a psychedelic therapy on the horizon, Oregon's licensed psilocybin service centers offer a real-world blueprint for patient-centered care. This article examines how leading facilities are applying individualized dosing, facilitator trust, and supportive environments and what that means for future clinical use.
Smarter than AI: A Commentary on Serendipitous Drug Discovery
One in four drugs traces its origin to an unexpected discovery — from penicillin to GLP-1s now projected to reach $100 billion by 2030. This commentary makes the case for why human observation and patient-centered real-world data remain our most powerful tools for breakthrough drug development, even in the age of AI.
Interview with Josh Hardman of Psychedelic Alpha
UBC’s interview with Josh Hardman explores the rapidly evolving psychedelics landscape, from regulatory challenges and REMS requirements to the role of psychotherapy, stigma, and real-world evidence in treatment adoption. The conversation highlights the importance of scientific rigor, balanced expectations, and patient-centered evidence generation as psychedelic-assisted therapies move closer to potential FDA approvals.
More from UBC.
Built for the full product lifecycle — our solutions span evidence, safety, and patient access.
Purpose-built for RWE.
Unmatched in post-marketing research.
Decades of epidemiology, medical, scientific, and data science expertise — at your service.
Talk to Our TeamLet's talk evidence.
Whether you're in early strategy or late-stage development, our team is ready to help you build a smarter RWE program.
Contact UBC →
Thank You for Connecting with UBC
.
What You Can Expect Next
.
- Leverage automation to move fast
- Always give customers a human to chat to
- Automate customer support and close leads faster
Get Ready to Change Your Business
.
Service Request
Bekki Bracken Brown
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.